New play­ers are jump­ing in­to an old vac­cine game as pan­dem­ic pan­ic spreads fast — putting their tech to the test

25 minutes ago
R&D

UP­DAT­ED: FDA’s golodirsen CRL: Sarep­ta’s Duchenne drugs are dan­ger­ous to pa­tients, of­fer­ing on­ly a small ben­e­fit. And where's that con­fir­ma­to­ry tri­al?

Yesterday
Regulatory

UP­DAT­ED: FDA hands off its lat­est whirl­wind drug OK as Hori­zon hus­tles would-be block­buster to the mar­ket

Yesterday
Pharma
Regulatory

As­traZeneca plans to spend $535M-plus to ex­pand its R&D net­work and man­u­fac­tur­ing ops in France

Yesterday
Pharma

What do Mass Gen­er­al, the NCI and Mayo Clin­ic have in com­mon? They rou­tine­ly blow off an FDA rule on post­ing tri­al re­sults

Yesterday
R&D

GSK’s ‘break­through’ BC­MA can­cer drug gets a pri­or­i­ty re­view — and a big win for the on­col­o­gy R&D team

Yesterday
R&D

BeiGene lines up its first shot at crack­ing the megablock­buster PD-1 mar­ket for lung can­cer. But can they over­come un­der­dog sta­tus?

Yesterday
R&D

'Y­ou be­trayed that du­ty': For­mer con­gress­man Chris Collins sen­tenced to 26 months in jail for in­sid­er trad­ing

2 days ago
People

Bernie Sanders goes af­ter Bio­Mar­in's shot at a record drug price, threat­en­ing to break the patent

2 days ago
Bioregnum
People

Rev­o­lu­tion Med shoots for $100M+ IPO — and di­vulges some se­crets about that Warp Dri­ve buy­out

4 days ago
R&D

At #JPM20, two CEOs, two rad­i­cal­ly dif­fer­ent ther­a­pies, and a fight to chase down sick­le cell

5 days ago
Cell/Gene Tx
Pharma

No­vo Nordisk's block­buster Ozem­pic wins FDA la­bel boost with CV in­di­ca­tion

5 days ago
R&D

First Chi­nese biotech on Nas­daq in two years draws $104M

6 days ago
IPOs

Bio­Marin ex­ecs dis­cuss some eye-pop­ping num­bers for the price of val­rox — but haven't we heard this be­fore?

6 days ago
R&D

#JPM20: Five years af­ter first PC­SK9, No­var­tis goes for win as Sanofi moves on, Am­gen sal­vages what's left

6 days ago
R&D

Neon Ther­a­peu­tics makes one last re­treat, sell­ing it­self cheap in a bar­gain base­ment M&A deal

6 days ago
Deals
R&D

#JPM20: Af­ter a year of NASH col­laps­es, all eyes on two biotechs

Last week
R&D

Gala­pa­gos beefs up its fi­bro­sis pipeline, las­so­ing 4 more pro­grams and tak­ing a stake in small Cana­di­an part­ner

Last week
Deals

Nek­tar aban­dons opi­oid drug af­ter a unan­i­mous 27-0 re­buff from FDA ad­comm

Last week
R&D

Four years af­ter 'moon­shot' launch, Patrick Soon-Sh­iong has a big re­veal: a sin­gle pa­tient

Last week
R&D

Still to be ap­proved in­clisir­an gets red car­pet treat­ment by UK's NHS in deal with No­var­tis

Last week
Deals

New Adap­ti­m­mune man­age­ment scores con­fi­dence boost with up to $897M+ Astel­las deal

Last week
Deals

Amar­in's Vas­cepa reigns supreme in fish oil bat­tle, as As­traZeneca's ri­val fiz­zles

Last week
Pharma
R&D

Bio­phar­ma ends decade with near-record in­vest­ment — but is it go­ing to the right places?

Last week
IPOs
Venture
1234 Next page Last page